Alimera reports net revenue of $2.2 million in second quarter
Alimera Sciences reported second quarter net revenue of $2.2 million, up from $2.1 million in the first quarter and $179,000 in the same quarter of 2013, the company announced in a news release.
“We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with Iluvien than were treated in our clinical trials. Further, we experienced a 25% increase in Iluvien injections in the United Kingdom during the second quarter of 2014 compared to the prior quarter,” Dan Myers, Alimera president and CEO, said in the release.
Alimera plans to launch Iluvien (fluocinolone acetonide intravitreal implant) in France and Portugal during the fourth quarter. It re-submitted a new drug application for Iluvien to the U.S. Food and Drug Administration in April.
GAAP net income was $1.1 million, compared with GAAP net loss of $21.3 million a year ago. Non-GAAP adjusted net loss was $6.1 million, compared with non-GAAP adjusted net loss of $9.5 million a year ago.
Research and development expenses totaled $1.8 million, an 18% decrease from $2.2 million in the second quarter of 2013. General and administrative expenses totaled $2.8 million, a 17% increase from $2.4 million, and sales and marketing expenses totaled $3.1 million, a 37% decrease from $4.9 million.